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Abstract
The impact of obesity can be better understood by studying the growing medical and 
socioeconomic burden of this often neglected public health epidemic. Traditionally asso-
ciated with cardiovascular risk factors like hypertension, hyperlipidemia, and diabetes 
mellitus, morbid obesity has increasingly contributed to mortality among Western as 
well as Third World populations. Contemporary evidence has also consistently linked 
this patient cohort with a greater risk to develop coronary artery disease. Recent popula-
tion‐based registries indicate that 43 and 24% of all cases of coronary revascularization 
were performed in overweight and obese patients, respectively. In this context, although 
popular thought has reaffirmed the positive correlation between obesity and increased 
cardiovascular morbidity, some authors have opined a better clinical outcome in over-
weight and obese patients, a phenomenon they termed “obesity paradoxon.” Conflicting 
data and the possibility of confounding bias have festered an ongoing debate challenging 
this “obesity paradox.” In this review article, we present updated evidence and discuss 
the validity of the “obesity paradoxon” in a variety of clinical settings.
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1. Introduction
Obesity has traditionally been defined as a body mass index (BMI) value >30 kg/m2, and 
its prevalence in the Western world, according to recent epidemiological data, could be as 
high as 36.5% [1]. Evidence of the growing prevalence of obesity can be inferred from the 
USA, where almost 70% of the population has been classified as obese; a significant increase 
from the 25% reported forty years ago [2]. The clinical relevance of obesity and its cluster of 
associated disorders, like arterial hypertension, dyslipidemia, diabetes mellitus, and sleep 
apnea syndrome, are demonstrated by its persistent link to an increased morbidity as well as 
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 mortality [3, 4]. It is for this reason that initiatives detailing the primary and secondary pre-
vention of cardiovascular disease in overweight and obese patients have laid specific empha-
sis on the significance of weight loss so as to modify cardiovascular risk [5–7]. Obese patients 
have an increased preponderance to develop atherosclerotic disease, especially coronary 
artery disease, which is characterized by a reduced sensitivity to insulin, enhanced free fatty 
acid turnover, increased basal sympathetic tone, a hyper‐coagulable state, and finally with 
promotion of systemic inflammation [8, 9]. Population‐based data suggest that 43 and 24% 
of all coronary revascularization in recent years were carried out in overweight and obese 
patients, respectively [10]. It has been speculated that the obese patient cohort is somehow 
associated with a clinical outcome far worse than that of a normal weight patient, and this 
theory is further substantiated by the existence of evidence describing the causative associa-
tion of morbid obesity in cardiovascular disease. Interestingly, contemporary studies have 
recently elucidated the role of an “obesity paradoxon,” describing the protective effect of 
obesity (when considering postoperative morbidity and mortality) in patients receiving either 
surgical or minimally invasive coronary revascularization [11]. This observation suggesting a 
better clinical outcome for obese patients is not only restricted to the clinical setting of coro-
nary revascularization, as similar data have also been reported in cases of an acute myocardial 
infarction and heart failure [12, 13].
In this review article, we attempt to present an overview and summarize the evidence docu-
mented on “obesity paradoxon” in coronary artery disease.
2. Stable coronary artery disease
The correlation of BMI with clinical endpoints in the setting of interventional coronary 
revascularization from a single‐center experience in patients (n = 3571) receiving balloon 
angioplasty was first reported in 1996 [14]. A detailed study of the in‐hospital outcomes 
suggested higher rates of mortality (2.8% vs. 0.9% vs. 3.7%; p < 0.001) in normal weight 
and obese patients as compared to overweight patients. This bias could also noted in the 
patients’ need for blood transfusions (11.9% vs. 7.4% vs. 8.4%; p = 0.003) and their corre-
sponding rise in creatinine value >1 mg/dl (3.6% vs. 1.8% vs. 1.8%; p = 0.018). Interestingly, 
the rates of myocardial infarction did not reflect any such patient group preference 
(3.5% vs. 3.4% vs. 4.7%; p = n.s.). The multicenter BARI registry evaluated the BMI of 3634 
patients undergoing elective revascularization [2108 by interventional procedure (PCI) and 
1526 by surgery (CABG)] at study entry between 1988 and 1991 [15]. Initial analyses of 
the results elicited a correlation between the body mass index and an increased risk of a 
major in‐hospital event in the PCI arm. At the five‐year follow‐up interval, this correlation 
between BMI and mortality existed only in the CABG arm. The final results from the BARI 
registry suggested an inverse relationship between BMI and in‐hospital outcome post‐PCI 
without any major difference in long‐term follow‐up. Interestingly, although the study 
by Gruberg et al. [11] did indicate an inverse relationship in the 9633 patients evaluated 
between 1994 and 1999 at the 12‐month follow‐up for mortality (10.6% vs. 5.7% vs 4.9%: 
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p < 0.0001), rates of myocardial infarction (7.4% vs. 7.0% vs. 6.7%: p = 0.66) and target vessel 
 revascularization (20.2% vs. 22.0% vs. 22.4%: p = 0.16) did not vary significantly. Certain 
post‐procedural clinical events like arterial hypertension, pulmonary congestion, impair-
ment of renal function, bleeding events, access site complications, as well as those leading 
to mortality were seen more often in underweight patients as compared to the overweight 
and obese patient cohort.
The Scottish Coronary Revascularization Register offers another perspective to this 
debate. In contrast to previous all‐comers trials, this study included only those patients 
(n = 4880) undergoing elective PCI between 1997 and 2006, and without any known his-
tory of coronary artery disease. Patients evaluated to have a BMI in the range between 27 
and 30 kg/m2 were linked with lower all‐cause mortality after 5 years of follow‐up as com-
pared to other weight groups. The introduction of a blanking time (<30 days) to exclude 
periprocedural events as well as an adjustment to different baseline data did not impact 
the outcome of their study [16]. These conclusions were reaffirmed in the APPROACH 
registry, where a collective of 310,121 patients were treated conservatively (n = 7801), 
by PCI (n = 7017), or by CABG (n = 15,601) [17]. Lower mortality rates were recorded 
among overweight and obese patients as compared to normal weight patients in the 
cohort treated conservatively. These findings were also consistent for the CABG as well as 
the PCI group. An interesting corollary to these results centered around the use of bare‐
metal stents (BMS) as well as a discussion on the meta‐analysis of these single trials, sug-
gesting an inverse relationship between BMI and the clinical outcome after  stenting [18]. 
The results from studies of the balloon angioplasty and the BMS era are in stark contrast 
to other studies conducted in this timeframe, wherein patients receiving any of the two 
stents, DES or BMS, did not observe the “obesity paradoxon.” An additional note in this 
context is summarized by the study of Poston et al. conducted in 1631 patients, suggest-
ing that normal weight patients were older than obese or overweight patients at the time 
of hospital admission [18]. The 1‐year follow‐up mortality and risk for procedure revision 
were comparable in both groups.
In the TAXUS trials, of the 1307 patients stratified according to BMI and type of stent used 
(BMS versus DES) [20], higher rates of BMS in‐stent restenoses were observed in obese and 
overweight patients than in normal‐weight patients (29.2% vs. 30.5% vs. 9.3%; p = 0.01). 
The patients receiving DES had major cardiac event (MACE) rates skewing in favor of nor-
mal weight patients, and however, the clinical event rates in these different patient groups 
did not vary significantly. Subsequent results obtained from the German DES.DE registry 
would also validate these findings [21]. A total of 5806 patients assimilated from 98 sites in 
Germany were included in this registry for DES patients and followed up over a period of 
12 months. The results would summarize suggestions made in previous trials, stating that 
the baseline comorbidity index was higher in obese patients as compared to overweight 
and normal weight patients, while the rates of in‐hospital events were similar in all three 
groups. The follow‐up after 1 year indicated no significant variability in mortality rates 
(3.3% vs. 2.4% vs. 2.4%; p = 0.17), myocardial infarction (2.8% vs. 2.3% vs. 2.3%; p = 0.45), 
target vessel revascularization (10.9% vs. 11.7% vs. 11.6%; p = 0.56), and major bleeding 
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(2.5% vs. 2.1% vs. 2.8%; p = 0.53) between normal weight, overweight, and obese patients, 
respectively (Table 1).
3. Acute coronary syndrome
The essential difference between stable coronary artery disease and an acute myocardial 
infarction is the existence of a pro‐inflammatory state with different forms of hemodynamic, 
rhythmogenic, and hemostatic disturbance in the latter. Although the “obesity paradoxon” 
phenomenon has been evaluated in the patient population, there is lack of homogenous data 
establishing a potential link between BMI and clinical events in patients with acute myocardial 
infarction. Data analyses of the 6359 acute coronary syndrome (ACS) patients included in the 
PREMIER and TRIUMPH registries drawn to establish a relationship between BMI and survival 
rate yielded novel results [22]. BMI and mortality rates shared an inverse relationship (9.2% vs. 
6.1% vs. 4.7%; p < 0.001) irrespective of demographic age and sex distribution. The KAMIR reg-
istry yielded similar results in its 3824 ST‐elevation myocardial infarction patient collective [23]. 
The baseline characteristics defined an older group of normal weight patients, with impairment 
of left ventricular ejection fraction and having a higher comorbidity index. The study eventu-
ally summarized that normal weight patients were associated with higher mortality rates.
An attempt to reaffirm this inverse relationship between BMI and clinical outcome in this 
scenario, however, was not possible in many other similarly conducted trials [24, 25]. Our 
research working group analyzed data from 890 patients diagnosed with ST‐elevated 
 myocardial infarction and followed them up for a duration of 12 months. This group also 
constituted patients diagnosed with cardiogenic shock. Interestingly, results indicated that 
clinical events did not vary significantly between all three weight groups, thus challenging 
the premise of the “obesity paradox” [26] (Table 2).
Author Year n Follow‐up 
(months)
Mortality Myocardial 
infarction
Target vessel 
revascularization
Renal 
insufficiency
Vascular 
complications
Ellis et al. [14] 1996 3571 12 + – – + +
Gurm et al. [15] 2002 3634 60 + n.a. n.a. n.a. –
Gruberg et al. [11] 2002 9633 12 + – – + –
Poston et al. [19] 2004 1631 12 – n.a. – n.a. n.a.
Nikolsky et al. [20] 2005 1301 12 – – – n.a. n.a.
Romero‐Corral 
et al. [18]
2006 250,  
152
45 + n.a. n.a. n.a. n.a.
Oreopoulos et al. [17] 2009 31,  
021
46 + n.a. n.a. n.a. n.a.
Hastie et al. [16] 2010 4880 60 + n.a. n.a. n.a. n.a.
Akin et al. [21] 2012 5806 12 – – – – –
Table 1. Overview of literature addressing the “obesity paradox” in patients suffering from stable coronary artery 
disease undergoing coronary angiography and/or revascularization.
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4. Rationale for the “obesity paradox”
The growing incidence of obesity can be construed from data suggesting an increase of 37% 
from 13.6 to 18.6%, in the cases of self‐reported obesity, among men aged 35–49 since 1970. 
Epidemiological factors attributed to the development of obesity and cardiovascular disease 
like arterial hypertension and diabetes mellitus are also on the rise [29, 30]. Recent efforts 
directed to reducing cholesterol levels and prevention of damaging smoking habits have 
helped sustain a decline in mortality from an acute coronary event. Frequent vessel revascu-
larization has also possibly played a role in this positive development [31–33]. This, however, 
does not discount the influence of the metabolic syndrome and its link to various cardiovas-
cular risk factors. Overweight and obese patients are derivatives of this syndrome, and the 
continual process of endothelial dysfunction and inflammation is often associated with the 
risk of developing atherosclerosis.
Evidence of this correlation constitutes an interesting paradox where better survival rates 
in an acute coronary event are real despite an increased incidence of obesity. This perti-
nent question has festered an ongoing debate as to the existence of the “obesity paradoxon” 
 phenomenon in the spectrum of coronary artery disease [10–26].
An examination of current literature indicates that certain published data, essentially that 
comprising retrospective information, have claimed a U‐shaped nonsignificant trend to sug-
gest lower survival among underweight patients as compared to normal or mildly overweight 
patients. This, however, could be the result of a technical bias, which unfortunately cannot be 
fully corrected by statistical means.
A detailed analysis of these patient groups has suggested that up to 2% of patients who are 
underweight are likely to suffer from comorbid conditions, including malignancies, heart 
failure, malnutrition, and multi‐organ dysfunction (MODS). This patient group also hap-
pens to constitute a significantly older age group demographic as compared to normal and 
obese patients [10, 11, 15], and clear evidence has linked elderly and frail patients to signifi-
cantly poorer clinical outcomes regardless of management or reperfusion strategy [34, 35]. 
Author Year N Follow‐up 
(months)
Mortality Myocardial 
infarction
Target vessel 
revascularization
Renal 
insufficiency
Vascular 
complications
Kosuge et al. [25] 2008 3076 hospital – n.a. n.a. n.a. n.a.
Kang et al. [23] 2010 3824 12 + – – n.a. n.a.
Camprubi et al. [24] 2012 824 hospital – n.a. n.a. n.a. n.a.
Bucholz et al. [22] 2012 6359 12 + n.a. n.a. n.a. n.a.
Li et al. [27] 2013 1429 12 – – – n.a. n.a.
Shehab et al. [28] 2014 4379 1 – – – n.a. n.a.
Akin et al. [26] 2015 890 12 – – – – –
Table 2. Overview of literature addressing the “obesity paradox” in patients suffering from acute coronary syndrome, 
including cardiogenic shock, undergoing coronary revascularization.
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An  interesting highlight in this respect is the influence of increasing age with its concomitant 
comorbidities on weight change [36–38]. The possibility of chronic disease leading to grad-
ual weight loss had not been factored into presented trials. Another important confounding 
observation was the increased tendency of obese patients receiving diagnosis and treatment 
at an earlier stage in comparison with lean patients.
A recent survey of >130,000 patients suggested that patients with higher BMI adhere more 
sincerely to guidelines with regard to the use of standard drugs such as aspirin, beta‐ blockers, 
acetylcholinesterase inhibitors, angiotensin II receptor blockers, as well as lipid‐lowering 
drugs and are increasingly likely to undergo invasive diagnostic and therapeutic interventions 
[15, 18, 21]. Additionally, overweight and obese subjects tended to be more stable at presenta-
tion, with the general constellation describing a patient lacking hemodynamic compromise, 
having a lower Killip class and also a preserved or less impaired ventricular function, which 
in turn proffers a better prognosis to the existing clinical scenario. These preliminary results 
present a clear challenge to the “obesity parodoxon” phenomenon.
Novel theories explaining the post‐PCI “obesity paradoxon” hypothesize that obese 
patients have “larger vessels” somehow instituting a beneficial effect. A further consolida-
tion of this hypothesis naturally suggests that post‐PCI outcome is significantly worse in 
patients with smaller vessels [39, 40]. The pharmacology of antithrombotic drugs is another 
interesting topic of discussion in this regard. The use of a standard dose rather than weight‐
adjusted dosages precludes accurate measurement of the pharmacokinetic and pharma-
codynamic effects of these medications in each patient. For example, the standard dose 
could very well be too high for an underweight patient (as calculated by BMI) resulting in 
significant bleeding events and is associated with a higher mortality rate [41]. Similarly, 
the sheath‐to‐artery size ratio varies in different BMI groups, and this could influence the 
rates of vascular complications [15]. These superficial differences observed in the context 
of a periprocedural event can reflect on the perceived improved survival noted among 
overweight patients [11, 42].
An absolute limiting factor in most studies centers around the use of BMI as a measure of 
obesity. The inadequate documentation of obesity distribution questions the plausibility 
of several results as this vital information has a significant impact in the clinical scenario. 
For example, central obesity has been associated with a poorer clinical outcome [43]. Other 
parameters such as waist circumference, waist‐to‐hip ratio, and weight change have not 
found mention in several of these trials [44–47]. Additionally, the inherent limitation of all 
these trials hypothesizing the “obesity paradoxon” is that they are an observational retrospec-
tive registry.
The failure to analyze potentially confounding variables such as physical inactivity, unin-
tended weight loss, the influence of socioeconomic factors, as well as the short follow‐up of 
these registries may have contributed to additional bias. Any existing relationship between 
obesity and in‐hospital and short‐term survival may have been lost, and the longer patients 
were followed. The possible buildup of the detrimental effects of obesity overtime could also 
have been studied in an extended follow‐up period, perhaps establishing a link to increased 
late mortality [48, 49].
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The “obesity paradoxon” hypothesis hinges on certain questionable data. The proponents of 
this theory claim that replete adipose tissue plays the role of an endocrine organ [50] produc-
ing soluble tissue necrosis factor receptor and hence ensues the protective effect [51].
Conversely, higher levels of thrombotic factors as well as elevated plasminogen activator 
inhibitor‐I in patients who are morbidly obese (BMI > 40 Kg/m2) probably contribute to the 
higher adjusted rates of post‐PCI mortality seen in this patient group [52].
The suggestion, in early studies, that there exists an inverse relationship between underweight 
patients and outcomes in heart failure is what heralded the concept of “obesity paradoxon.” 
However, an in‐depth analysis of recently published data questions any such claim in the set-
ting of coronary artery disease and modern coronary intervention. In fact, there is insufficient 
evidence or even proof of concept to veer away from the classic relationship between risk fac-
tors, confounding variables and prognostic outcomes. These association studies are limited 
not only by the lack of pathophysiological underpinnings, but also hindered by the use of 
descriptive notions and confounding variables with unknown impact to substantiate their 
results. While analyzing the neutralizing results of the German DES.DE Registry [21], the per-
ception of obesity demonstrating a protective effect on outcomes post‐PCI is seriously held in 
doubt and the provocative construct of an “obesity paradoxon” debased, as this hypothesis 
was never really substantiated in the clinical setting of coronary artery disease and PCI.
Finally, the support expressed by associative studies (in light of little or no statistical and biological 
evidence) leading to the hypothesis of an “obesity paradox” has been effectively debunked by the 
interpretation of recent clinical data. A contrarian concept would only hold traction if supported 
by plausible pathophysiology. In the context of coronary artery disease and PCI, there are hardly 
any convincing explanation and certainly no clinical data to justify an “obesity paradoxon.”
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